Price$1.49+0.08 (+6.05%)
01:45 PM04:00 PM
News · 26 weeks45-21%
2025-12-142026-06-07
Mix3690d
- Insider19(53%)
- SEC Filings9(25%)
- Other4(11%)
- Leadership2(6%)
- Earnings2(6%)
Latest news
25 items- INSIDERChief Commercial Officer Mitchell Micah covered exercise/tax liability with 6,529 shares, decreasing direct ownership by 6% to 102,949 units (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- INSIDERChief Medical Officer Kovelman Harry covered exercise/tax liability with 7,635 shares, decreasing direct ownership by 7% to 100,983 units (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- INSIDERChief Financial Officer Henry David A covered exercise/tax liability with 10,050 shares, decreasing direct ownership by 2% to 435,124 units (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- INSIDERDirector Kirk Thomas F bought $50,803 worth of shares (40,002 units at $1.27), increasing direct ownership by 6% to 693,865 units (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- INSIDERAmendment: Chief Commercial Officer Mitchell Micah sold $77,689 worth of shares (90,231 units at $0.86), decreasing direct ownership by 45% to 109,478 units (SEC Form 4)4/A - MYOMO, INC. (0001369290) (Issuer)
- INSIDERDirector Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- INSIDERChief Medical Officer Kovelman Harry sold $32,239 worth of shares (32,000 units at $1.01), decreasing direct ownership by 23% to 108,618 units (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- SECSEC Form SD filed by Myomo Inc.SD - MYOMO, INC. (0001369290) (Filer)
- INSIDERDirector Kirk Thomas F bought $68,243 worth of shares (75,006 units at $0.91), increasing direct ownership by 14% to 628,863 units (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- INSIDERDirector Manko Joseph M. Jr. bought $173,908 worth of MYO (201,197 units at $0.86) (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- INSIDERNew insider Manko Joseph M. Jr. claimed ownership of 2,108,578 units of MYO (SEC Form 3)3 - MYOMO, INC. (0001369290) (Issuer)
- INSIDERChief Commercial Officer Mitchell Micah sold $77,689 worth of shares (90,231 units at $0.86), decreasing direct ownership by 45% to 109,478 units (SEC Form 4)4 - MYOMO, INC. (0001369290) (Issuer)
- SECSEC Form DEFA14A filed by Myomo Inc.DEFA14A - MYOMO, INC. (0001369290) (Filer)
- SECSEC Form DEF 14A filed by Myomo Inc.DEF 14A - MYOMO, INC. (0001369290) (Filer)
- PRMyomo Announces Participation in Upcoming Investor ConferencesMyomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in two upcoming investor conferences. On May 20, Myomo's President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will participate virtually in a fireside chat as part of Alliance Global Partners Annual Healthcare Company Showcase. The fireside chat will begin at 11:20 a.m ET. The registration link for the conference can be found here. Chief Financial Officer David Henry will present at Sidoti's Virtual Micro Cap Conference
- SECMyomo Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MYOMO, INC. (0001369290) (Filer)
- PRMyomo Appoints Joseph M. Manko to its Board of DirectorsMyomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. ("Joe") Manko Jr. as a director effective May 9, 2026, to serve until the 2027 annual meeting of stockholders. With this appointment, Myomo has seven directors. Mr. Manko is an accomplished investor with over 25 years of experience in investment banking, private equity, asset management and corporate strategy. Mr. Manko is currently the Senior Principal of Horton Capital Management LLC ("The Horton Fund"), a significant shareholder in the Company. Mr.
- SECSEC Form 10-Q filed by Myomo Inc.10-Q - MYOMO, INC. (0001369290) (Filer)
- SECMyomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MYOMO, INC. (0001369290) (Filer)
- PRMyomo Reports First Quarter 2026 Financial and Operating ResultsRevenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026. "Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing
- SECSEC Form PRE 14A filed by Myomo Inc.PRE 14A - MYOMO, INC. (0001369290) (Filer)
- PRMyomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S.Myomo, Inc. (NYSE:MYO), a wearable medical robotics company and manufacturer of the MyoPro® powered arm brace, announces expanded access to the MyoPro device through Ottobock Care clinics nationwide. Ottobock Care will offer the MyoPro through its clinics across the country, helping individuals with upper extremity impairment caused by stroke, brachial plexus injury, or other neurological conditions regain function and improve quality of life. "The MyoPro fits well into our strategy to position our O&P clinics as leaders in providing enhanced neuro-robotic solutions to our patient population. Ottobock Care already assists patients with lower limb mobility issues with a variety of orthot
- PRMyomo to Report First Quarter 2026 Financial Results on May 7Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call star
- SECAmendment: SEC Form 10-K/A filed by Myomo Inc.10-K/A - MYOMO, INC. (0001369290) (Filer)
- PRMyomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient EngagementMyomo, Inc. (NYSE:MYO), a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb paralysis, announces the launch of the Myomo® Mobile App, a new digital tool designed to support clinicians and patients throughout the MyoPro® experience. The Myomo Mobile App is designed to make MyoPro care more intuitive, more connected, and more data-informed. For clinicians, the app provides a streamlined mobile interface for customizing EMG settings in person or remotely, including gain, threshold, range of motion, and advanced settings. It also gives clinicians visibility into patient usage and device configurations, helping support m
MYO FAQ
7 questionsWhat does Myomo Inc. do?
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The...Where does MYO stock trade?
Myomo Inc. (MYO) is listed on AMEX.What sector and industry is MYO in?
Myomo Inc. operates in the Health Care sector, Industrial Specialties industry.When did Myomo Inc. go public?
Myomo Inc. (MYO) completed its IPO in 2017.What are analysts saying about MYO?
Myomo Inc. has had 3 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $700.00 price target on 2024-07-31. Recent price targets range from $650.00 to $700.00.What companies are similar to MYO?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare MYO side-by-side with any of them on Quantisnow.How can I track MYO on Quantisnow?
Quantisnow aggregates Myomo Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MYO to receive live email and push alerts on every new disclosure.